Navigation Links
Additional Data From Multiple Phase 1 and 2 Studies of S*BIO's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
Date:6/1/2011

efficacy in alleviating MF-associated splenomegaly and constitutional symptoms at a dose that induces minimal myelosuppression. Once-daily dosing was well tolerated, with manageable GI toxicity as the main side effect. Given the lack of myelosuppression, SB1518 was of particular importance for MF patients with impaired hematopoiesis. Thirty patients (88%) showed reductions in palpable splenomegaly; 15 (44%) showed decreases of >50% and seven (21%) showed a reduction of 100%. At Week 24, 23 patients (68%) showed spleen reduction (3% to 50% by MRI volumetric assessment). Nine patients (26%) had reduction in splenomegaly by >35% reduction. Splenic reduction of 50% by PE correlated with a 25% reduction in spleen volume by MRI. Twelve patients (35%) had reduction in splenomegaly by >25%. Spleen response rates were as high among patients with low baseline platelet counts as those with normal baseline counts. Responses were durable; response duration among those achieving an IWG MRT response ranged from 1 to 164+ days (median, not reached). Two patients met IWG-MRT criteria for clinical improvement in hemoglobin and 1 for platelet count. At the 6 month visit, a significant reduction (>2 point improvement) was observed for MF associated symptoms, including abdominal pain, cough, and night sweats.About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around kinases and histone deacetylases (HDAC). SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has now completed Phase 2 trials for MF.  It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO's lead HDAC inhibitor, SB939, is currently in Phase 2 trials. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 tr
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
2. Hope Paige Designs Medical ID Bracelets Now Available in 1,100 Additional Locations
3. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
4. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
5. Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations
6. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
7. Rosetta Genomics Announces Issuance of Additional U.S. Patent
8. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
9. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
10. Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010
11. Additional 8 Products of DK Sinopharma, Inc. are Included in 2010 Provincial Medical Insurance Catalogs in 4 Separate Provinces in the Peoples Republic of China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, announced the start of a phase 1 ... will explore the safety, pharmacokinetics,pharmacodynamics and anti-tumor activity ... MT110 targets the epithelial cell adhesion molecule ...
... an oncolytic product, WOBURN, Mass., April 22 ... treatments for cancer and the prevention,of infectious disease, ... (FDA) has approved the design of a single, ... OncoVEX(GM-CSF) in,previously treated patients with metastatic melanoma. The ...
Cached Medicine Technology:Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 2Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 3Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 4Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 5BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 2BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 3
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... DALLAS April 22, 2014 Researchers at UT ... people suffering from depression . , A ... major mechanism by which ghrelin (a hormone with natural ... identified a potentially powerful new treatment for depression in ... , The study, published online in April,s ...
(Date:4/22/2014)... Washington, DC (April 22, 2014) The International ... May 22-26 in Seattle, Washington. The theme of ... life" means in a networked and digital society. ... and attended by over 2,200 Communication scholars representing ... largest scholarly international communication conference in the world. ...
(Date:4/22/2014)... 22 April 2014. The latest scientific advances and emerging ... Failure 2014, the main annual meeting of the Heart ... (ESC). Journalists will also hear breaking news on acute ... Heart Failure, which is part of the main congress. ... Athens, Greece, at the Megaron Athens International Conference Centre ...
(Date:4/22/2014)... ARBOR, Mich. Nearly 7 in 10 Americans ... a new national survey by researchers at the University ... with children under the age of 18 at home, ... more likely than other adults to support universal coverage ... appear in the Journal of the American Medical ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2
... 11, 2008 The American Cancer Society announced today ... for Exemplary Leadership in Tobacco Control. The awards are ... L. Terry, M.D., who led the landmark 1964 Surgeon ... and other illnesses. Dr. Terry,s courageous and groundbreaking work ...
... Deanna Vankessel, author of the recently published G lobal Markets ... to offer extensive expertise on the recent FDA premarket approval recommendation of ... , , MRG,s Deanna Vankessel is available ... , How ...
... Begin in December - , , ... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), ... neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. These ... breast cancer positive for the ErbB-2 receptor (also known as HER-2 ...
... Health Company (NYSE Alternext: FHC) has announced that the U.S. ... Committee has unanimously voted that the company,s second-generation female condom, ... , , The Advisory ... condition that the FC2 Female Condom,s instructions for use continue ...
... with ribavirin for previously untreated children with chronic hepatitis ... , KENILWORTH, N.J., Dec. 12 Schering-Plough ... the U.S. Food and Drug Administration (FDA) has granted ... USP) combination therapy for use in previously untreated patients ...
... Case Medical Center in conjunction with Sodexo Health Care Services ... 24/6 unit, the original certified kosher hot food vending machine. ... in the state of Ohio, offering patients and their caregivers ... , University Hospitals prides itself ...
Cached Medicine News:Health News:American Cancer Society recognizes international tobacco control leaders 2Health News:American Cancer Society recognizes international tobacco control leaders 3Health News:American Cancer Society recognizes international tobacco control leaders 4Health News:American Cancer Society recognizes international tobacco control leaders 5Health News:American Cancer Society recognizes international tobacco control leaders 6Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 2Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 3
... has been designed specifically for the ... involved in ward rounds. It is ... dosages, and consultations that are requested ... Registrar during Ward round examinations and ...
... tracking and billing. This ... Handheld application, a complete ... CPT™ and ICD-9-CM codes ... Designed for any medical ...
In addition to the patient data OB-on-Call contains a comprehensive Medications list displaying related drugs by brand name, generic title, and usage description notes....
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
Medicine Products: